Annexon, Inc. (ANNX) vs Zevra Therapeutics, Inc. (ZVRA)

A side-by-side comparison of Annexon, Inc. and Zevra Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Annexon, Inc. logo
ANNX
Annexon, Inc.
$660M
$4.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Zevra Therapeutics, Inc. logo
ZVRA
Zevra Therapeutics, Inc.
$634M
$10.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANNX vs ZVRA

growth of $100 · dividends reinvested · last 6y
ANNX -76.4% (-21.4%/yr)ZVRA +122.9% (+14.3%/yr)ZVRA compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$24$223
ANNX ZVRA

ANNX vs ZVRA: by the numbers

  • •ANNX is the larger company ($660M vs $634M market cap).
  • •ZVRA is profitable (42.82% net margin) while ANNX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricANNXZVRA
P/E ratioN/A11.53
Forward P/EN/A9.68
P/S ratioN/A4.66
P/B ratio3.552.91
EV / EBITDAN/A12.11
FCF yieldN/A5.13%

Profitability

MetricANNXZVRA
Gross margin0.00%84.52%
Operating margin0.00%-3.98%
Net margin0.00%42.82%
ROE-108.93%26.77%
ROIC-101.43%12.93%

Growth (annualized)

MetricANNXZVRA
Revenue CAGR (5Y)N/A36.81%
Total return CAGR (5Y)-26.29%3.75%

Frequently asked

Is ANNX or ZVRA more profitable?
ZVRA runs the higher net margin — ANNX at 0.00% versus ZVRA at 42.82%.
How have ANNX and ZVRA total returns compared?
Over the past 5 years, ANNX delivered -26.29% and ZVRA delivered 3.75% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ANNX analysisFull ZVRA analysisInteractive comparison tool

Dig into the metrics

Zevra Therapeutics P/E ratioAnnexon ROEZevra Therapeutics ROEAnnexon operating marginZevra Therapeutics operating marginAnnexon revenue growthZevra Therapeutics revenue growthAnnexon free cash flowZevra Therapeutics free cash flow

Annexon & Zevra Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.